ReviewAntimicrobial agents and chemotherapy2016
Is There Potential for Repurposing Statins as Novel Antimicrobials?
Review in Antimicrobial agents and chemotherapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 2 syntheses or guidelines pooled it, 131 citations in OpenAlex.
- Effect of Statins onGE Portuguese journal of gastroenterology · 2022Pooled it
- Gut bacterial microbiome composition and statin intake-A systematic review.Pharmacology research & perspectives · 2020Pooled it
- Trial
- Selective statin therapy and nasal staphylococcal colonisation: a retrospective case-control study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Cholesterol sulfate signaling facilitates persistent colonization of mucoid-coccoid H. pylori in gastric environment.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- The therapeutic potential of atorvastatin in treatment ofFrontiers in veterinary science · 2026Article
- Immunometabolism at the crossroads of infection: mechanistic and systems-level perspectives from host and pathogen.Immunometabolism (Cobham, Surrey) · 2025Review
- Statins do not reduce the parasite burden during experimentalAntimicrobial agents and chemotherapy · 2025Article
- Mechanistic insights into the multitarget synergistic efficacy of farrerol and β-lactam antibiotics in combating methicillin-resistantAntimicrobial agents and chemotherapy · 2025Article
- Assessing the Antibacterial Potential and Biofilm Inhibition Capability of Atorvastatin-Loaded Nanostructured Lipid Carriers via Crystal Violet Assay.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Lovastatin and Resveratrol Synergistically Improve Wound Healing and Inhibit Bacterial Growth.International journal of molecular sciences · 2025Article
- Statin use during intensive care unit stay is associated with improved clinical outcomes in critically ill patients with sepsis: a cohort study.Frontiers in immunology · 2025Article
- Statins, Allies against Antibiotic Resistance?Current medicinal chemistry · 2025Review
- In Vitro synergy of Farnesyltransferase inhibitors in combination with colistin against ESKAPE bacteria.PloS one · 2025Article
- Triglyceride levels are associated with 30-day mortality in intensive care patients: a retrospective analysis in the MIMIC-IV database.European journal of medical research · 2024Article
- Article
- Statin Use and Reduced Risk of Pneumonia in Patients with Melioidosis: A Lung-Specific Statin Association.Annals of the American Thoracic Society · 2024Article
- Unveiling the Antibacterial Properties of Statins: AnAdvances in pharmacological and pharmaceutical sciences · 2024Article
- Prospective and challenges of locally applied repurposed pharmaceuticals for periodontal tissue regeneration.Frontiers in bioengineering and biotechnology · 2024Review
- Statins and Cardiomyocyte Metabolism, Friend or Foe?Journal of cardiovascular development and disease · 2023Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statins are members of a class of pharmaceutical widely used to reduce high levels of serum cholesterol. In addition, statins have so-called "pleiotropic effects," which include inflammation reduction, immunomodulation, and antimicrobial effects. An increasing number of studies are emerging which detail the attenuation of bacterial growth and in vitro and in vivo virulence by statin treatment. In this review, we describe the current information available concerning the effects of statins on bacterial infections and provide insight regarding the potential use of these compounds as antimicrobial therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.